Invivyd

NEWS

Adagio Raises $336 Million to Support Development of COVID-19 Antibody Candidate

The new financing round was led by RA Capital Management, in tandem with new investors Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another unnamed investor from the health care space.

April 19, 2021

3 min read

Brandon May

JOBS

IN THE PRESS

Press Releases

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 6, 2026

April 6, 2026

1 min read

Press Releases

Invivyd Announces Presentation at the World Vaccine Congress Washington

March 30, 2026

5 min read

Press Releases

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

March 5, 2026

7 min read

Press Releases

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

March 5, 2026

23 min read

Press Releases

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026

March 3, 2026

1 min read

Press Releases

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

March 3, 2026

1 min read

Press Releases

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

February 24, 2026

15 min read

Press Releases

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

February 3, 2026

9 min read

Press Releases

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

January 20, 2026

13 min read

Press Releases

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights

January 8, 2026

18 min read